Article

Distal myopathies.

Centre for Neuromuscular and Neurological Disorders, University of Western Australia, Perth, Western Australia, Australia.
Current Opinion in Neurology (Impact Factor: 5.73). 11/2005; 18(5):504-10. DOI: 10.1097/01.wco.0000175936.23945.b6
Source: PubMed

ABSTRACT The distal myopathies are a heterogeneous group of disorders that pose a challenge to both the clinician and geneticist. This article summarizes the findings of recent clinical, genetic and molecular studies and the current diagnostic approach to this group of patients.
Publications over the past 5 years describe a number of new clinical phenotypes and genetic loci and further emphasize the overlap in clinical phenotype between a number of these disorders and between the distal and limb girdle myopathies and hereditary inclusion body myopathies. Recent studies have led to the identification of the genes and mutations responsible for early onset (Laing) myopathy and tibial (Udd) myopathy, and for distal myopathy with rimmed vacuoles (Nonaka), which has been shown to be allelic with quadriceps sparing hereditary inclusion body myopathy (IBM2), and have elucidated the underlying pathogenetic mechanisms in these conditions. New diagnostic approaches using magnetic resonance imaging, and a blood-based assay for dysferlin deficiency, have also been reported.
These findings have important implications for future genetic linkage and gene expression studies and for the diagnostic approach to patients with a distal myopathy phenotype. They also hold promise for the eventual development of therapies for this group of disorders.

0 Bookmarks
 · 
90 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Zusammenfassung Rezessive Mutationen im Anoctamin-5 (ANO5)-Gen wurden vor kurzem bei Patienten mit Gliedergürtelmuskeldystrophie (LGMD Typ 2L) und bei Patienten mit distaler Myopathie vom Typ Miyoshi identifiziert. Wir beschreiben fünf deutsche Patienten mit Muskeldystrophien infolge von ANO5-Mutationen. Es erfolgte ein Screening der häufigen Mutation c.191dupA sowie der Mutationen c.1295C>G und p.R758C durch Sequenzierung der Exone 5, 13 und 20. Zum Nachweis neuer Mutationen wurde der gesamte kodierende Abschnitt des ANO5-Gens sequenziert. Phänotypisch wiesen 3 Patienten eine LGMD auf, ein Patient eine distale Myopathie vom Typ Miyoshi und die Schwester eines Patienten eine asymptomatische HyperCKämie. Das Manifestationsalter war 64, 38 und 40 Jahre bei den Patienten mit LGMD und 23 Jahre bei dem Patienten mit distaler Myopathie. Die 4 manifesten Patienten zeigten eine auffallend asymmetrische Muskelbeteiligung. Alle Patienten trugen zumindest auf einem Allel die Mutation c.191dupA. Zwei Patienten mit LGMD waren homozygot für diese Genveränderung. Der dritte LGMD-Patient und seine Schwester mit HyperCKämie waren compound heterozygot für die Mutationen c.191dupA und eine neue Mutation p.T548I. Der Patient mit distaler Myopathie wies auf dem zweiten Allel die Mutation p.R758C auf. Mutationen im ANO5-Gen scheinen eine relativ häufige Ursache einer Muskeldystrophie in Deutschland darzustellen. Eine sehr späte Erstmanifestation ist möglich und auch eine asymptomatische HyperCKämie kann vorkommen. Klinisch ist eine asymmetrische Manifestation typisch.
    Der Nervenarzt 12/2011; DOI:10.1007/s00115-011-3325-4 · 0.86 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Congenital myasthenic syndromes are a clinically and genetically heterogeneous group of rare diseases resulting from impaired neuromuscular transmission. Their clinical hallmark is fatigable muscle weakness associated with a decremental muscle response to repetitive nerve stimulation and frequently related to postsynaptic defects. Distal myopathies form another clinically and genetically heterogeneous group of primary muscle disorders where weakness and atrophy are restricted to distal muscles, at least initially. In both congenital myasthenic syndromes and distal myopathies, a significant number of patients remain genetically undiagnosed. Here, we report five patients from three unrelated families with a strikingly homogenous clinical entity combining congenital myasthenia with distal muscle weakness and atrophy reminiscent of a distal myopathy. MRI and neurophysiological studies were compatible with mild myopathy restricted to distal limb muscles, but decrement (up to 72%) in response to 3 Hz repetitive nerve stimulation pointed towards a neuromuscular transmission defect. Post-exercise increment (up to 285%) was observed in the distal limb muscles in all cases suggesting presynaptic congenital myasthenic syndrome. Immunofluorescence and ultrastructural analyses of muscle end-plate regions showed synaptic remodelling with denervation-reinnervation events. We performed whole-exome sequencing in two kinships and Sanger sequencing in one isolated case and identified five new recessive mutations in the gene encoding agrin. This synaptic proteoglycan with critical function at the neuromuscular junction was previously found mutated in more typical forms of congenital myasthenic syndrome. In our patients, we found two missense mutations residing in the N-terminal agrin domain, which reduced acetylcholine receptors clustering activity of agrin in vitro. Our findings expand the spectrum of congenital myasthenic syndromes due to agrin mutations and show an unexpected correlation between the mutated gene and the associated phenotype. This provides a good rationale for examining patients with apparent distal myopathy for a neuromuscular transmission disorder and agrin mutations.
    Brain 06/2014; 137. DOI:10.1093/brain/awu160 · 10.23 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Muscular dystrophy arises from ongoing muscle degeneration and insufficient regeneration. This imbalance leads to loss of muscle, with replacement by scar or fibrotic tissue, resulting in muscle weakness and, eventually, loss of muscle function. Human muscular dystrophy is characterized by a wide range of disease severity, even when the same genetic mutation is present. This variability implies that other factors, both genetic and environmental, modify the disease outcome. There has been an ongoing effort to define the genetic and molecular bases that influence muscular dystrophy onset and progression. Modifier genes for muscle disease have been identified through both candidate gene approaches and genome-wide surveys. Multiple lines of experimental evidence have now converged on the transforming growth factor-β (TGF-β) pathway as a modifier for muscular dystrophy. TGF-β signaling is upregulated in dystrophic muscle as a result of a destabilized plasma membrane and/or an altered extracellular matrix. Given the important biological role of the TGF-β pathway, and its role beyond muscle homeostasis, we review modifier genes that alter the TGF-β pathway and approaches to modulate TGF-β activity to ameliorate muscle disease.
    FEBS Journal 09/2013; 280(17). DOI:10.1111/febs.12266 · 3.99 Impact Factor